plerixafor / Generic mfg. - LARVOL DELTA

Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature review. (PubMed, Ther Adv Hematol) - "Plerixafor plus granulocyte colony-stimulating factor (G-CSF) significantly improved mobilization success over cyclophosphamide plus G-CSF (73.6% vs 49.5%), though with slightly delayed engraftment. However, advanced stage, IgD subtype, and inadequate pre-ASCT response could discount the effectiveness of ASCT. INPLASY2025110069."

Clinical data • Journal • Real-world evidence • Review • Hematological Malignancies • Multiple Myeloma • Oncology • Transplantation

An open-label, multi-center Phase 2 study to assess the safety and efficacy of burixafor (GPC-100) and propranolol with G-CSF for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma (ASH 2025) - P2 | "Mediantimes to neutrophil and platelet engraftment were 11 days (range 11-17 days) and 15 days (range 11-27days), respectively.ConclusionsBurixafor, in combination with propranolol and G-CSF, demonstrated an excellent safety profile andeffectively mobilized sufficient HPCs for AHCT, including patients previously treated with lenalidomideand daratumumab. Notably, burixafor enabled same-day administration with leukapheresis, offering akey advantage over other CXCR4 inhibitors, such as plerixafor and motixafortide through its rapidmobilization kinetics. Its favorable safety profile, characterized by minimal adverse events, supporting itspotential clinical utility."

Clinical • IO biomarker • P2 data • Cardiovascular • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hypotension • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • CD34 • CXCR4

AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN HODGKIN LYMPHOMA: A 16-YEAR SINGLE-CENTER EXPERIENCE FROM EHU 1ST NOVEMBER OF ORAN, ALGERIA (EBMT 2026) - "ASCT was administered as first-line consolidation therapy in 53 patients with advanced-stage disease (stage III–IV) and in 102 patients with relapsed or refractory R/R HL.CD34⁺ hematopoietic stem cells were mobilized using granulocyte colony-stimulating factor (G-CSF) alone (filgrastim or lenograstim) at a dose of 15 µg/kg/day for 5 days, or in combination with plerixafor in cases of mobilization failure...The EAM regimen included a total dose of etoposide 800 mg/m², cytarabine 8 g/m², and melphalan 140 mg/m²... ASCT is a safe and effective treatment for patients with Hodgkin lymphoma. Using predominantly fresh grafts, the procedure showed low treatment-related mortality, rapid hematologic recovery, high remission rates, and durable long-term outcomes."

Clinical • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Transplantation • CD34

IMPACT OF CD34⁺ CELL DOSE AND GROWTH FACTOR SUPPORT ON EARLY MORBIDITY AND NON-RELAPSE MORTALITY AFTER AUTOLOGOUS STEM CELL TRANSPLANT FOR LYMPHOMA (EBMT 2026) - "33% of patients received plerixafor and/or an additional cycle of cytarabine or cyclophosphamide to mobilise progenitor cells. We did not demonstrate a significant association between CD34+ dose in ASCT and 180-day NRM. CD34+ doses <4×10⁶/kg were associated with a higher rate of ICU admission and a composite adverse outcome. We found similar clinical outcomes with pegfilgrastim compared with filgrastim."

CNS Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • Transplantation

EVALUATION OF RELATED HEMATOPOIETIC STEM CELL DONORS IN THE CONTEXT OF FACT-JACIE STANDARDS IMPLEMENTATION (EBMT 2026) - "Among apheresis donors (median age 38.5 years; range 3–70; 100 females), 22 required more than one apheresis (10.7%), 30 (14.6%) required catheter placement, and 18 (8.8%) received plerixafor in addition to filgrastim. Stem cell donation, whether from peripheral blood or bone marrow, is a safe procedure in the context of implementing FACT-JACIE quality standards. The most frequent positive tests in our setting are syphilis and Chagas disease, which did not contraindicate donations. Conversely, detection of SCD was a rare event in our series and among patients with normal hemoglobin levels."

Bone Marrow Transplantation • Breast Cancer • CNS Disorders • Genetic Disorders • Hepatitis B • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Movement Disorders • Musculoskeletal Pain • Pulmonary Embolism • Sickle Cell Disease • Solid Tumor

ATIDARSAGENE AUTOTEMCEL IN METACHROMATIC LEUKODYSTROPHY: SAFETY CONSIDERATIONS FROM REAL-WORLD PRACTICE (EBMT 2026) - "Mobilised peripheral blood (G-CSF + plerixafor) was used as the CD34⁺ source in all cases, with a median collection of 37.6×10⁶ CD34⁺ cells/kg (range 19.2–62.9). All patients underwent myeloablative single-agent busulfan conditioning... The robust engraftment, sustained ARSA reconstitution and early outcomes seen in most patients in this real-world cohort of 12 patients with MLD treated with arsa-cel are consistent with those seen in the clinical development programme; however, this cohort highlights the critical importance of systematic, long-term post-therapy monitoring for the continued evaluation of the risk–benefit profile in the real world setting."

Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • Gene Therapies • Hematological Disorders • Hematological Malignancies • Hepatology • Leukemia • Metabolic Disorders • Rare Diseases • Thrombocytopenia • CD34

HEMATOLOGIC SHIFTS DURING HPC(A) AND THEIR INFLUENCE ON COLLECTION EFFICIENCY AND CD34+ CELL YIELD (EBMT 2026) - "The majority of aphereses (n = 264, 91.3%) were performed after mobilization with either G-CSF alone (n = 136) or G-CSF plus plerixafor (n = 128) at standard doses. ΔPLT emerged as the only robust predictor across all models, showing a positive association with CE1 and CE2 and an inverse association with AY. The remaining Δ-variables offered no independent contribution once multicollinearity was accounted for. Intra-apheresis platelet dynamics may therefore serve as a practical biomarker of apheresis system performance."

CD34

LESS INFLAMMATION, SAME SURVIVAL: PLERIXAFOR MOBILIZATION REDUCES ENGRAFTMENT CRS IN PAEDIATRIC HSCT COMPARED TO GCSF ALONE (EBMT 2026) - "Recipient outcomes evaluated included engraftment kinetics, CRS, engraftment syndrome, acute GVHD, mortality, relapse, TATMA, secondary graft dysfunction requiring romiplostim, SOS, day +15/+30 chimerism, viral reactivation, and immune reconstitution across CD4 subsets, NK and B cells at days +30, +60 and +90. The CD34:CD3 ratio differed significantly between mobilization strategies. G-CSF–only mobilization yielded grafts richer in CD34⁺ stem cells, whereas plerixafor-mobilized grafts were more T-cell enriched. These differences in graft biology did not translate into inferior clinical outcomes in the plerixafor group.Engraftment CRS was significantly lower in the plerixafor cohort and anakinra requirement for cytokine control was numerically reduced, indicating a lower inflammatory burden despite graft compositional differences.Immune recovery, survival, and complication profiles remained equivalent between mobilization strategies.Overall, plerixafor is a safe and..."

Acute Graft versus Host Disease • Bone Marrow Transplantation • Graft versus Host Disease • Immunology • Inflammation • Pediatrics • CD34

Tiered Fixed-Dose Plerixafor Resulted in Enhanced CD34+ Cell Mobilization and Collection with a Comparable Safety Profile Versus Weight-Based Plerixafor in Patients with Sickle Cell Disease: Results from the Ongoing BEACON Study of Autologous CD34+ Base-Edited Hematopoietic Stem Cells (BEAM-101) (TCT-ASTCT-CIBMTR 2026) - P1/2 | "Evaluate the effectiveness of fixed-dose vs weight-based plerixafor regimens in patients with SCD in the BEACON study 3 . Assess the safety profile of fixed-dose vs weight-based plerixafor"

Clinical • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • CD34 • CXCR4

Single Center, Inpatient Pediatric Experience of Autologous Collections Using Pre-Collection CD34 Rate of Rise for Gene-Modified Products for Hemoglobinopathies (TCT-ASTCT-CIBMTR 2026) - "Objectives: We describe our center's collection protocol and provide CD34 count rate of rise analysis following plerixafor mobilization in the inpatient pediatric setting...More data is needed to better understand if the rate of rise of CD34 counts can be utilized as a metric to predict mobilization efficacy and need for additional collection days or cycles. jhbklk"

Clinical • Gene Therapies • Genetic Disorders • Graft versus Host Disease • Hematological Disorders • Immunology • Pediatrics • Sickle Cell Disease • CD34

Safety Outcomes of CXCR4 Antagonists for Stem Cell Mobilization in Patients with Multiple Myeloma (TCT-ASTCT-CIBMTR 2026) - "CXCR4 antagonists plerixafor and motixafortide, when combined with G-CSF, are widely used to mobilize hematopoietic stem and progenitor cells. Integrating structured nursing assessments into mobilization protocols enhances patient safety and the overall mobilization experience. Future nursing-led initiatives should aim to refine toxicity prophylaxis and management—particularly for motixafortide—to optimize safety and promote best practices in patient-centered mobilization care."

Clinical • Hematological Malignancies • Immunology • Multiple Myeloma

Peripheral Blood Stem Cell Collection for Patients with Multiple Myeloma Undergoing Autologous Transplant after Quadruplet Induction (TCT-ASTCT-CIBMTR 2026) - "Introduction: Quadruplet induction regimens, including daratumumab, bortezomib/cafilzomib, lenalidomide and dexamethasone (DVRD/DKRD) are increasingly used for patients with newly diagnosed multiple myeloma (MM)...Most patients in both CD34 groups (88%) received GCSF+plerixafor for stem cell mobilization. 6 patients received chemo-mobilization with cyclophosphamide, all in the high CD34 group... 16% of patients who received quadruplet induction had suboptimal PBSC collection prior to autoHCT, more commonly in older patients. The number of induction cycles and lenalidomide dose did not significantly impact the yield of stem cell collection. A lower CD34 collection did not adversely impact the engraftment, response rates or survival outcomes."

Clinical • Hematological Malignancies • Multiple Myeloma • Transplantation • CD34

Multi-Omic and Functional Characterization of Bone Marrow Regulatory T cells for Enhanced GVHD Prevention (TCT-ASTCT-CIBMTR 2026) - "We developed a CyTOF panel to validate findings in BMMCs and PBMCs from healthy adults (n=8), and compared Tregs from donors mobilized with granulocyte colony-stimulating factor (G-CSF) alone or G-CSF plus plerixafor (n=8)...3 . Evaluate the functional impact of specific Treg surface markers, such as CXCR4, by interpreting results from CRISPR-Cas9 gene editing experiments and suppression assays."

Bone Marrow Transplantation • Graft versus Host Disease • Hematological Malignancies • Immunology • CSF3 • CXCR4 • FOXP3

Reducing Resource Utilization and Costs through a Revised Stem Cell Mobilization and Collection Algorithm in Multiple Myeloma (TCT-ASTCT-CIBMTR 2026) - "Evaluate the impact of the revised mobilization algorithm on clinical outcomes, including CD34+ yield, plerixafor utilization, and mobilization success rates. Assess the cost and resource utilization benefits achieved through algorithm-driven decision- making and nursing-led workflow optimization in autologous stem cell transplant mobilization."

HEOR • Hematological Malignancies • Multiple Myeloma • CD34

Adverse Drug Effects Following Motixafortide for Hematopoietic Progenitor Cell Mobilization in Patients with Multiple Myeloma (TCT-ASTCT-CIBMTR 2026) - "Introduction Despite the use of plerixafor, a low-affinity, short-acting CXCR4 inhibitor, over 25% of multiple myeloma (MM) patients are unsuccessful at mobilizing their target CD34+ hematopoietic progenitor cells (HPCs)...Standard premedications included acetaminophen, diphenhydramine, famotidine, and montelukast. Due to treatment emergent adverse events (TEAEs), intravenous dexamethasone 10 mg was added to the premedication regimen starting May 2025...Premedication, longer monitoring, and reaction treatment medication use with motixafortide impacts resource utilization for patients undergoing mobilization. (1) To describe the efficacy outcomes of using motixafortide for mobilization in a real world MM population (2) To describe the treatment emergent adverse effects of motixafortide when used in a real world MM population (3) To describe injection reaction rates with motixafortide following addition of dexamethasone as premedication"

Clinical • Dermatology • Hematological Malignancies • Immunology • Multiple Myeloma • Pruritus • Urticaria • CD34 • CXCR4

An Open-Label, Multi-Center Phase 2 study to Assess the Safety and Efficacy of Burixafor (GPC-100) and Propranolol with G-CSF for the Mobilization of Hematopoietic Progenitor Cells in Patients with Multiple Myeloma (TCT-ASTCT-CIBMTR 2026) - P2 | "All received lenalidomide-based induction therapy, with 70% also receiving daratumumab. Assess the efficacy of the above treatment combination. Demonstrate the fast kinetics of mobilization of burixafor, allowing for leukapheresis within an hour after burixafor administration, as opposed to 10-12 hours with other CXCR4 inhibitors, plerixafor and motixafortide."

Clinical • IO biomarker • P2 data • Cardiovascular • Constipation • Diabetes • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hypotension • Multiple Myeloma • Musculoskeletal Diseases • Musculoskeletal Pain • CD34 • CXCR4

A Cohort Comparison of CXCR4 Antagonists for Multiple Myeloma Mobilization (TCT-ASTCT-CIBMTR 2026) - "Plerixafor and motixafortide are CXCR4 antagonists used with G-CSF to mobilize CD34⁺ stem cells by disrupting CXCL12–CXCR4. Further prospective and risk-balanced studies are needed to confirm these signals, identify patients most likely to benefit, and clarify operational and cost implications to guide agent selection. Compare Day 1 CD34 count in patients getting 2 different CXCR4 Antagonists"

Amyloidosis • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia • CD34 • CXCL12

Outcomes of Stem Cell Mobilization Using Plerixafor Plus G-CSF in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: A Single Institute Experience. (TCT-ASTCT-CIBMTR 2026) - "(1) Efficacy of Plerixafor with G-CSF is stem cell mobilization for autologous hematopoietic stem cell transplantation in lymphom patients. (2) Factors increasing the likelihood of requiring more apheresis days (3) Impact on engraftment with the number of apheresis days required and final CD34+ cell dose collected."

Clinical • B Cell Lymphoma • Bone Marrow Transplantation • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Indolent Lymphoma • Lymphoma • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Primary Central Nervous System Lymphoma • T Cell Non-Hodgkin Lymphoma • Transplantation

Reduction of Stem Cell Collection Pheresis Time in Patients with Large Numbers of Circulating CD34+ with Upfront Plerixafor Use (TCT-ASTCT-CIBMTR 2026) - "Reducing collection time from 5 to 4 hours achieved a 95% rate of adequate CD34+ yield. Shortened collections may enhance patient comfort, optimize workload, and reduce unnecessary product storage. Larger studies are warranted to confirm these findings and assess lowering the collection time for circulating CD34>100 cells/μl."

Clinical • Germ Cell Tumors • Hematological Malignancies • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • CD34 • CXCR4

Phase 1b Study of Pirtobrutinib, Plerixafor, and Lisocabtagene Maraleucel in Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Mantle Cell Lymphoma (TCT-ASTCT-CIBMTR 2026) - "3 . Recognize the potential clinical impact of this trial in addressing unmet needs in R/R CLL/SLL and MCL, particularly for double-refractory patients, and how correlative analyses may inform future cellular therapy strategies."

P1 data • Chronic Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Lymphoma • Mantle Cell Lymphoma • Non-Hodgkin’s Lymphoma • Small Lymphocytic Lymphoma

Type of Mobilization Agent Impacts CD34+ Cell Collection Yields for Patients with Sickle Cell Disease Undergoing Gene Therapy: A Single-Center Analysis (TCT-ASTCT-CIBMTR 2026) - "Brand plerixafor appears to lead to significantly higher post-mobilization WBC and peripheral blood CD34+ cells as well as total CD34+ cells/kg collected during initial apheresis cycle when compared to generic plerixafor for patients with SCD undergoing PM for CGT. Mobilization time as well as apheresis collection factors may also impact CD34+ yield, which warrants further investigation to achieve collection success. 1) To investigate patient and clinical factors that may impact the success of peripheral stem cell mobilization and collection in adult and pediatric patients with sickle cell disease undergoing cellular gene therapy."

Clinical • Gene therapy • Bone Marrow Transplantation • Gene Therapies • Genetic Disorders • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Sickle Cell Disease • CD34

Failed PBSC Mobilization: Combination Dose-Escalated G-CSF + GM-CSF Successfully Rescues Stem Cell Collection and Allows Autologous Transplantation (TCT-ASTCT-CIBMTR 2026) - "Most patients received BEAM (n=35, 56%) or melphalan (n=25, 40%) conditioning. After initial failed mobilization with G-CSF ± plerixafor alone, remobilization with combination G-CSF + GM-CSF improves CD34 + cell collection yield, with 86% of patients adequately mobilizing to allow for AHCT, and with timely engraftment and favorable post-AHCT outcomes. Combination G-CSF + GM-CSF is an effective strategy for poor mobilizers. Prospective multicenter studies remain warranted, including direct comparison with chemotherapy mobilization strategies."

Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Transplantation • CD34 • CSF2

Impact of Motixafortide on Apheresis Chair Utilization and Mobilization Efficiency Compared to Plerixafor in Autologous Stem Cell Transplant Candidates (TCT-ASTCT-CIBMTR 2026) - "Motixafortide plus G-CSF demonstrated comparable apheresis efficiency to plerixafor-based mobilization in the multiple myeloma patient population, with similar mean chair and procedure run times. These findings suggest both mobilization strategies provide equivalent operational efficiency in routine clinical practice."

Hematological Malignancies • Multiple Myeloma • Transplantation • CD34 • CXCR4

Collection and Manufacture of Autologous HSC Gene Therapy Cell Product for Patients with Sickle Cell Disease (SCD) and Transfusion Dependent Thalassemia (TDT): A Real World Gene Therapy (ReGenT) Consortium Report. (TCT-ASTCT-CIBMTR 2026) - "SCD received plerixafor mobilization while TDT received a combination of plerixafor and G-CSF. Two SCD patients received motixafortide... With ongoing data collection from the other centers, we demonstrate more significant challenges in mobilization, collection and manufacturing in the post-commercialization era as manufacturing scales nationally, compared to reports from the original clinical trial experience and the importance of need to improve manufacturing, increased apheresis days/cycle. Variability in CD34 + collection highlights the need for better predictive strategies to allow for optimal collection and allow for alternate mobilization and apheresis adjustments. 1."

Clinical • Gene therapy • Real-world • Real-world evidence • Gene Therapies • Genetic Disorders • Hematological Disorders • Sickle Cell Disease • CD34

Improved Hematopoietic Stem Cell Mobilization for Gene Therapy of Hemoglobinopathies Using Single Agent Motixafortide (TCT-ASTCT-CIBMTR 2026) - P1 | "HSC mobilization for SCD is limited to single agent plerixafor P , a CXCR4 antagonist, since G- CSF is associated with an increased risk of vaso-occlusive events VOEs and death...To mitigate known local injection site and potential systemic reactions to M, all patients received prophylactic H-1 and H-2 antagonists and acetaminophen, with 86% receiving additional montelukast...Additional studies are warranted to determine the ideal timing with apheresis and prophylactic medication regimen. 1- limitations of peripheral blood stem cell mobilization in sickle cell disease 2- Adverse effects of motixafortide especially in patients with SCD 3-Feasibility of using motixafortide for mobilization in beta thalassemia"

Gene therapy • Beta-Thalassemia • Dermatology • Gene Therapies • Hematological Disorders • Hematological Malignancies • Multiple Myeloma • Pruritus • Sickle Cell Disease • Urticaria